Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial
Fig 5
Frequencies of the most commonly observed adverse events by treatment arm.
Frequencies are expressed as percentages of participants who were assessed for AEs after treatment. AE: adverse event; DA: diethylcarbamazine and albendazole; IDA: ivermectin, diethylcarbamazine and albendazole.